Precipio

Yahoo Finance • 23 hours ago

Precipio Announces its Q2-2025 Financial Results

NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for... Full story

Yahoo Finance • 14 days ago

Precipio Announces Q2-2025 Shareholder Update Call

NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will include updates o... Full story

Yahoo Finance • last month

Precipio amends warrant agreement, to receive $1.2M in cash

NEW HAVEN, Conn. - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), currently trading at $15.57 with a market capitalization of $23.14 million, announced Friday it has modified an agreement with its largest warrant holder... Full story

Yahoo Finance • last month

Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless

NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with its largest warrant holder, amending the existing structure from cash exercise of w... Full story

Yahoo Finance • last month

Arena Group Holdings vs. Precipio: 2 New Top 100 Stocks to Buy. Precipio’s the Buy.

Medicine labratory by gorodenkoff via iStock There were 10 new additions to Barchart’s Top 100 Stocks to Buy on Monday. Of the 10, Arena Group Holdings (AREN) and Precipio (PRPO) stand out among the bunch of high-flying stocks. Arena Gro... Full story

Yahoo Finance • 5 months ago

Precipio Announces Q4 and year-end 2024 Shareholder Update Call

NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will incl... Full story

Yahoo Finance • 6 months ago

Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO), announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA –... Full story

Yahoo Finance • 2 years ago

Precipio Announces Q3-2023 Shareholder Update Call

NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00 PM ET. The call will include updates... Full story

Yahoo Finance • 2 years ago

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doub... Full story

Yahoo Finance • 2 years ago

Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

NEW HAVEN, Conn., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO), announces that the combination of revenue growth and cost cutting initiatives has reduced Cash Burn From Operations (C... Full story

Yahoo Finance • 2 years ago

Precipio Continues to Sign New HemeScreen™ Customers

NEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M. In a re... Full story

Yahoo Finance • 2 years ago

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

NEW HAVEN, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduc... Full story

Yahoo Finance • 2 years ago

Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO), announces its Pathology Division has in August exceeded the monthly breakeven revenue goal which, if continued, cause... Full story

Yahoo Finance • 2 years ago

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

NEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that it has entered into a collaboration agreement with a NY-based academic healthcare institution to joint... Full story

Yahoo Finance • 2 years ago

Precipio Shares Growth Catalysts For HemeScreen

NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s shareholders call several growth catalysts that management has been tracking. The Compan... Full story

Yahoo Finance • 2 years ago

Precipio Announces Q1-2023 Shareholder Update Call

NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET. The call will include updates on all of t... Full story

Yahoo Finance • 2 years ago

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new pathology services customer to utilize Precipio’s diagnostic services. Based on... Full story

Yahoo Finance • 2 years ago

Precipio Signs Another HemeScreen™ Customer

NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory. With each additi... Full story

Yahoo Finance • 2 years ago

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

NEW HAVEN, Conn., April 27, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the... Full story

Yahoo Finance • 2 years ago

Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined

NEW HAVEN, Conn., April 19, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.(NASDAQ: PRPO), announces that Q1-2023 product revenues have surpassed product revenues during the two prior quarters of 2022, and ex... Full story